Isaei Elham, Sobhanipoor Mohammad Hossein, Rahimlou Mehran, Firouzeh Nima
Medical Mycology and Bacteriology Research Center, Kerman University of Medical Sciences, Kerman, Iran.
School of Medicine, Bam University of Medical Sciences, Bam, Iran.
Trop Dis Travel Med Vaccines. 2024 Dec 15;10(1):25. doi: 10.1186/s40794-024-00235-y.
Tuberculosis represents a significant menace to health, leading to millions of cases and fatalities each year. Traditional diagnostic methods, while effective, have limitations, necessitating improved tools. Aptamers possessing remarkable specificity single-stranded DNA or RNA molecules promising in TB diagnosis due to their adaptability and precise biomarker detection capabilities. In this study, we aimed to evaluate the research on aptamer applications in TB diagnosis, evaluating the efficacy, limitations, and future prospects. The present systematic review study followed PRISMA guidelines, including peer-reviewed studies on aptamer efficacy in TB diagnosis. Eligibility criteria covered experimental and human studies on TB diagnosis, prognosis, progression, and treatment response. Of 1165 identified studies, 35 met inclusion criteria. Aptamers were utilized for MTB and mycobacterial antigen detection, showcasing notable sensitivity and specificity. Targeted antigens included ESAT-6, HspX, MPT 64, and IFN-γ. Various aptamer-based assays, such as electrochemical, fluorescent, and immunosensors, demonstrated effectiveness. Multiplex assays, particularly for IFN-γ, showed enhanced diagnostic accuracy. Aptamer-based assays exhibited discrimination between active TB and other conditions, showcasing their diagnostic value. Aptamers, especially in conjunction with nanomaterials, show promise in developing advanced TB biosensors with superior detection capabilities. Cost-effective devices with heightened sensitivity for clinical and screening use are crucial for TB control, emphasizing the need for ongoing research in this field.
结核病对健康构成重大威胁,每年导致数百万病例和死亡。传统诊断方法虽然有效,但存在局限性,因此需要改进工具。适体是具有显著特异性的单链DNA或RNA分子,因其适应性和精确的生物标志物检测能力,在结核病诊断中具有应用前景。在本研究中,我们旨在评估适体在结核病诊断中的应用研究,评估其疗效、局限性和未来前景。本系统综述研究遵循PRISMA指南,纳入了关于适体在结核病诊断中疗效的同行评审研究。纳入标准涵盖了关于结核病诊断、预后、进展和治疗反应的实验研究和人体研究。在1165项已识别的研究中,35项符合纳入标准。适体被用于检测结核分枝杆菌和分枝杆菌抗原,显示出显著的敏感性和特异性。靶向抗原包括早期分泌性抗原靶6(ESAT-6)、热休克蛋白X(HspX)、结核分枝杆菌蛋白抗原64(MPT 64)和干扰素-γ(IFN-γ)。各种基于适体的检测方法,如电化学、荧光和免疫传感器,都证明了有效性。多重检测,特别是针对IFN-γ的检测,显示出更高的诊断准确性。基于适体的检测方法能够区分活动性结核病和其他病症,显示出其诊断价值。适体,尤其是与纳米材料结合使用时,在开发具有卓越检测能力的先进结核病生物传感器方面显示出前景。开发具有更高灵敏度的经济高效的临床和筛查用设备对于结核病控制至关重要,这凸显了该领域持续研究的必要性。